Second cases of Lyme rash are often reinfection

NEW YORK (Reuters Health) – When the bulls-eye-shaped rash of Lyme disease reappears many months after treatment, the source is almost certainly a new tick bite and not a resurgence of the original infection, according to a new analysis of 17 patients. The study, published in the New England Journal of Medicine, is more evidence that proper antibiotic treatment is effective and that bacteria do not hide in the body for years, waiting to make a subsequent appearance. …

Scientists identify new risk gene for Alzheimer’s

(Blank Headline Received)CHICAGO (Reuters) – Two international teams of scientists have identified a rare mutation in a gene linked with inflammation that significantly increases the risk for the most common form of Alzheimer's disease, the first such discovery in at least a decade. The findings, published on Wednesday in the New England Journal of Medicine, offer new insights into the underpinnings of Alzheimer's, a deadly, brain-wasting disease that robs people of their memories, their independence and their lives. …

Study: are cancer patients’ hopes for chemo too high?

(Reuters) – At least two thirds of people with advanced cancer believed the chemotherapy they were receiving might cure them, even though the treatment was only being given to buy some time or make them comfortable, according to a U.S. survey. Researchers reported in the New England Journal of Medicine that 69 percent of patients who were terminally ill with lung cancer, and 81 percent with fatal colorectal cancer, did not understand that their chemotherapy was not at all likely to eliminate their tumors. …

Drug showed promise in clearing drug-resistant tuberculosis

CHICAGO (Reuters) – An antibiotic used to treat severe bacterial infections showed promise at treating a highly drug-resistant and deadly form of tuberculosis, U.S. government and South Korean researchers said on Wednesday. The study, published in the New England Journal of Medicine, is the first scientifically rigorous clinical trial of Pfizer’s antibiotic linezolid, or Zyvox, in patients with extensively drug-resistant TB (XDR-TB), which is resistant to at least four of the drugs most often used to treat the lung infection. …

Eat chocolate, win the Nobel Prize?

(Reuters) – Of all the chocolate research out there, the most unabashed tribute to the “dark gold” has to be a study just published in one of the world’s most prestigious medical journals. Drum roll, please. The higher a country’s chocolate consumption, the more Nobel laureates it spawns per capita, according to findings released in the New England Journal of Medicine. The Swiss, of course, lead the pack, closely followed by the Swedes and the Danes. The U.S. …

Bristol immune drug shows promise in three cancers

CHICAGO (Reuters) – An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells. Early-stage tests of the drug BMS-936558, known as an anti-PD-1 treatment, showed it was relatively safe and shrank tumors in three of the five cancer types studied, the team reported at the American Society of Clinical Oncology (ASCO) meeting on Saturday and published online in the New England Journal of Medicine. …

1 2